Phase 1b Study of CAR2Anti-CEA CAR-T Cell Hepatic Infusions for Pancreatic Carcinoma Patients With CEA+ Liver Metastases

Summary

This study is an open-label, single arm phase 1b safety study of CAR2 Anti-CEA CAR-T cell hepatic arterial infusions for pancreatic carcinoma patients with carcinoembryonic antigen positive (CEA+) liver metastases resistant to standard therapy who meet all other eligibility criteria.

Timeline

Start

2019-07-29

Primary completion

2020-01-19

Completion

2021-05-21

Outcome

Outcome not reported

Stopped (Enrollment): “Limited enrollment.”

Drugs

Indications